iBio is a clinical stage biotech developing AI designed antibody drugs for obesity and related heart and lung diseases. It last closed at $0.75 on Nov 17, up 5.86% on the day. IBIO reports earnings on Tue, Feb 9, 2027.
Only 1 firm rated IBIO in the past 90 days, not enough for a consensus
Average 12-month target
$7.00
▲ 835.7% upside
Based on 1 analyst who set a price target on IBIO in the past 90 days. The average target is $7.00, with a high of $7.00 and a low of $7.00, compared with the last close of $0.75.
Low $7.00Avg $7.00High $7.00
Blue marker: last close $0.75
Highest target$7.00
Average target$7.00
Lowest target$7.00
Latest rating changes
HC Wainwright & Co.Initiated
Sep 17Buy$7
Raymond JamesInitiated
Jun 8Buy$5
Date
Firm
Action
Rating
Price target
Sep 17
HC Wainwright & Co.
Initiated
Buy
$7
Jun 8
Raymond James
Initiated
Buy
$5
Loading…
Technical Analysis
IBIO · as of the Nov 17 close · updated after every close
Downtrend
The stock is 3% below its 20 day and 28% below its 50 day average. It is 115% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 42). The nearest support is the Pivot at $0.74, and the nearest resistance the Pivot R1 at $0.77.
Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 9.6%/day
Key levels
$3.8252 week high+409.3%
$1.61200 day average+114.7%
$1.20100 day average+60.0%
$0.9650 day average+28.0%
$0.84Swing high (Nov 11)+12.0%
$0.7720 day average+2.7%
$0.77Pivot R1+2.7%
$0.75Last close
$0.74Pivot−1.3%
$0.73Swing low (Oct 14)−2.7%
$0.71Pivot S1−5.3%
$0.6852 week low−9.3%
Indicators
RSI (14)
41.87
Middle of its range
Neutral
MACD
-0.05
Above its signal line
Bullish
Stochastic
28.6
Middle of its range
Neutral
ADX (14)
24.8
Weak trend
Williams %R
-58.3
Oversold below −80, overbought above −20
Neutral
CCI (20)
-77.9
Oversold below −100, overbought above 100
Neutral
Rate of change
−7.8%
Change over 10 sessions
Bearish
ATR (14)
$0.07
Typical daily range, 9.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 29.4%/day
Key levels
$3.8252 week high+409.3%
$1.61200 day average+114.7%
$1.20100 day average+60.0%
$0.9650 day average+28.0%
$0.84Swing high (Nov 11)+12.0%
$0.7720 day average+2.7%
$0.77Pivot R1+2.7%
$0.75Last close
$0.74Pivot−1.3%
$0.73Swing low (Oct 14)−2.7%
$0.71Pivot S1−5.3%
$0.6852 week low−9.3%
Indicators
RSI (14)
29.83
Oversold below 30
Oversold
MACD
-0.26
Below its signal line
Bearish
Stochastic
6.8
Near the bottom of its range
Oversold
ADX (14)
20.2
Weak trend
Williams %R
-91.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-111.0
Oversold below −100, overbought above 100
Oversold
Rate of change
−38.2%
Change over 10 sessions
Bearish
ATR (14)
$0.22
Typical daily range, 29.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IBIO
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how IBIO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow IBIO usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How IBIO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2008.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IBIO is in one of them and how their past IBIO trades turned out.
iBio is a biotechnology company that uses artificial intelligence to design antibody drugs. Its work focuses on obesity and related heart and lung conditions, including pulmonary hypertension linked to heart failure. Its lead candidate, IBIO-600, is in a Phase 1 clinical trial, and other candidates are in earlier preclinical development. No products are approved yet, so its intended customers are patients with these conditions and the clinicians who treat them. The company is based in New York and conducts its research at a laboratory in San Diego.